Nobel Biocare Dental Implants, The Brånemark Heritage

Overview, What Nobel Biocare Is and Why It Matters

Nobel Biocare is the implant company most directly descended from Per-Ingvar Brånemark's original 1965 osseointegration discovery, the work that created modern dental-implant dentistry as we know it. The company holds the longest unbroken clinical record in the field (forty-plus years of published Brånemark-protocol survival data), pioneered the All-on-4 protocol with Dr. Paulo Maló in 1998, and remains the global benchmark for full-arch immediate-loading systems through its current All-on-X and NobelActive ranges.

Nobel Biocare, Brand and Manufacturer Background

{{IMAGE_PLACEHOLDER:Nobel Biocare manufacturing or research facility, clean-room interior or Brånemark archive imagery}}

The company traces its lineage to Bofors Nobelpharma, the Swedish pharmaceutical company that licensed Brånemark's titanium-fixture invention in the late 1970s. Brånemark himself worked at the University of Gothenburg, where the original osseointegration discovery occurred during 1952–1965 microcirculation experiments in rabbit bone. The first edentulous-patient case (Gösta Larsson, 1965) carried Brånemark fixtures for the rest of his life, the lifetime case file is the longest single-patient implant follow-up in the literature.

Nobelpharma evolved through Procordia, into Nobel Biocare AB, into the current Nobel Biocare Group acquired by Danaher in 2014 and now part of Envista Holdings (NYSE: NVST). The company headquarters are in Kloten, Switzerland; manufacturing concentrates in Yorba Linda, California (USA), Mahwah, New Jersey (USA), and Karlskoga, Sweden. Total cumulative implants placed worldwide exceeds 13 million as of the most recent annual report.

Regulatory Clearances and Quality Standards

• FDA 510(k), clearances for the original Brånemark system from the early 1980s onwards; current K-numbers for Replace, Active, and BCC available through the FDA public database
• CE marking, full conformity to EU MDR (2017/745) since the 2024 transition deadline
• TGA Australia, registered Class IIb medical device
• CDSCO India, registered through the BIS Class C medical device pathway
• PMDA Japan, registered for clinical use

ISO 13485 across manufacturing sites; full lot-level traceability.

Surface Treatment and Osseointegration Profile

TiUnite is the Nobel Biocare proprietary surface, a moderately rough titanium oxide layer produced by anodisation in a phosphate-rich electrolyte. The result is a thicker oxide than machined titanium (0.6–10 µm vs <0.2 µm for machined), with a porous topography at the micro-scale that supports rapid bone-to-implant contact.

{{IMAGE_PLACEHOLDER:Scanning electron microscope image of TiUnite surface at 1000× magnification}}

Clinical evidence is substantial across the Nobel TiUnite ranges. Glauser et al. (2007) reported 96.0% TiUnite implant survival at 5 years across 1,920 implants in 506 patients, including immediate-load and posterior cases. The 10-year Brånemark Novum and equivalent cohorts maintain the 95–97% survival range, with the Maló All-on-4 cohort at the highest end (94.8% mandibular at 20 years).

The TiUnite hydrophilicity profile is more conservative than Straumann's SLActive, Nobel Biocare positioned the surface as a stable, well-documented chemistry rather than chasing the high-surface-energy preserved-storage approach. For the clinical case, TiUnite has the longest single-surface long-term cohort outside of SLA and is the surface most commonly published in immediate-load full-arch literature.

Surgical Protocol, How Nobel Biocare Is Placed

Drill Sequence and Torque Profile

Nobel Biocare uses brand-specific drill kits, different for the parallel-walled Replace Conical Connection, the tapered NobelActive, and the BCC ranges. Standard saline irrigation rate of 50 ml/min. Target insertion torque is 35–45 Ncm for delayed loading; immediate loading requires 45–70 Ncm depending on the protocol (NobelActive achieves higher torque in tapered placement).

Recommended Primary Stability Threshold

ISQ 65+ for delayed loading; ISQ 70+ for immediate loading; the All-on-4 protocol requires the four-implant Insertion-Torque Composite to meet documented gates (Maló protocol).

Available Connections

• NobelReplace Conical Connection (NRCC), the conventional posterior workhorse with platform-switching geometry
• NobelActive, tapered, immediate-load-optimised, internal conical connection with thread-switching design that condenses bone during placement
• NobelParallel Conical Connection (NPCC), for sites where parallel-walled fixtures are preferred (multi-unit cases)
• All-on-4 with multi-unit abutments, the Maló protocol that Nobel Biocare codified into product

Recommended Sites and Indications

NobelActive for immediate placement and immediate load; NobelReplace Conical for standard delayed loading; All-on-4 multi-unit configurations for full-arch; zygomatic compatibility through partner-prosthetic systems.

Prosthetic Options, What Sits On Top

• Cement-retained crowns, abutments with platform-switching on Conical Connection ranges
• Screw-retained crowns, for posterior cases prioritising retrievability
• Multi-unit abutments, 17°, 30° angulation for All-on-4 / All-on-6 / pterygoid placements
• NobelProcera CAD-CAM, Nobel's in-house digital prosthetic workflow
• NobelPearl, ceramic two-piece implant variant for aesthetic anterior

{{IMAGE_PLACEHOLDER:Prosthetic cross-section, NobelActive implant with multi-unit abutment + zirconia bridge}}

Indications and Contraindications

Indications. Single-tooth, multi-unit, full-arch (All-on-4 / All-on-6), immediate placement, immediate load, zygomatic-anchor pterygoid combinations.

Relative contraindications. Same general patient profile as Straumann, heavy bruxism, irradiated bone, uncontrolled diabetes, active periodontitis, smoking above ten cigarettes per day.

Absolute contraindications. Active head-and-neck cancer with current radiation; bisphosphonate therapy without coordinated cessation; severe untreated systemic disease.

What This Costs

Stunning Dentistry's Experience With Nobel Biocare

We have placed approximately 2,300 Nobel Biocare fixtures across fourteen years. The 924-implant formal audit included 248 Nobel fixtures, survival at four-year follow-up: 96.4%. We hold authorised-provider status; the most recent Nobel-supervised audit (February 2026) issued zero non-conformances.